New drug combination slows tumor growth for recurrent ovarian cancer

June 6, 2011 in Cancer

Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

Progression-free survival, the length of time that a patient doesn't experience any , was significantly improved in the women who received the new compared to those who received a standard treatment. A 52 percent reduction in the risk of was seen.

"This is good news for women with , as we are increasingly able to treat ovarian cancer as a chronic disease," said Dr. Aghajanian, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan-Kettering. "This is the first phase III trial to show a strong benefit for these patients using an antiangiogenic such as in combination with chemotherapy for ."

This study was a randomized, double-blind trial of patients with platinum-sensitive recurrent ovarian cancer - which means that the women have experienced a disease progression of greater than six months after completing their first-line chemotherapy.

"Ovarian cancer tends to present at late stage and about 80 percent of women recur after initially being treated with surgery and chemotherapy, so our ability to offer women a new is very important," says Dr. Aghajanian.

"This is good news for women with ovarian cancer, as we are increasingly able to treat ovarian cancer as a chronic disease," said Carol Aghajanian, MD, lead author and Chief of the Gynecologic Medical Oncology Service at Memorial Sloan-Kettering.

The study included 484 patients - 242 who received chemotherapy and bevacizumab and 242 who received chemotherapy and a placebo. All patients received chemotherapy in addition to either bevacizumab or the placebo and continued to receive bevacizumab or the placebo as "maintenance therapy," designed to maximize the benefit to patients, until they showed signs of disease progression. Disease progression was measured by CT scans that were taken every nine weeks throughout the study. The study was unblinded in February 2011 after demonstrating a positive treatment effect.

The women who received bevacizumab in addition to chemotherapy showed a 52 percent improvement in progression-free survival. Of the women who received bevacizumab and chemotherapy, 79 percent exhibited significant tumor shrinkage compared to 57 percent of the women who received the placebo and chemotherapy. In addition to the decrease in tumor size for those receiving bevacizumab and chemotherapy, researchers also found that the tumor shrinkage lasted for a longer time for those women.

"This study is extremely important because it demonstrates a clear, clinically meaningful response from bevacizumab in these cancers," said Dr. Aghajanian.

According to the National Cancer Institute, ovarian cancer accounts for approximately 3 percent of all cancers in women and is the fifth leading cause of cancer-related death among women in the United States. Ovarian cancer is the term that is typically used to encompass the group of diseases including epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and fallopian tube (FTC) cancer.

Provided by Memorial Sloan-Kettering Cancer Center

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Frequent heartburn may predict cancers of the throat and vocal cord

Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data ...

Cancer created 26 minutes ago | popularity not rated yet | comments 0

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Cancer created 2 hours ago | popularity 5 / 5 (1) | comments 0

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Researchers find possible 'master switch' in deadly brain cancer

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...

Cancer created 4 hours ago | popularity 3.5 / 5 (2) | comments 0 | with audio podcast


Researchers suggest boosting body's natural flu killers

A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...

Regenerating spinal cord fibers may be treatment for stroke-related disabilities

A study by researchers at Henry Ford Hospital found "substantial evidence" that a regenerative process involving damaged nerve fibers in the spinal cord could hold the key to better functional recovery by most stroke victims.

The secret lives, and deaths, of neurons

As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon—the "business end" of the neuron that sends electrical impulses to tissues or other ...

Anxious men fare worse during job interviews, study finds

Nervous about that upcoming job interview? You might want to take steps to reduce your jitters, especially if you are a man.

Breakthrough on Huntington's disease

Researchers at Lund University have succeeded in preventing very early symptoms of Huntington's disease, depression and anxiety, by deactivating the mutated huntingtin protein in the brains of mice.

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...